company background image
ONC

Oncolytics Biotech TSX:ONC Stock Report

Last Price

CA$1.72

Market Cap

CA$100.5m

7D

4.2%

1Y

-33.3%

Updated

15 Aug, 2022

Data

Company Financials +
ONC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ONC Stock Overview

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.

Oncolytics Biotech Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oncolytics Biotech
Historical stock prices
Current Share PriceCA$1.72
52 Week HighCA$2.96
52 Week LowCA$1.06
Beta1.73
1 Month Change35.43%
3 Month Change16.22%
1 Year Change-33.33%
3 Year Change102.35%
5 Year Change-64.50%
Change since IPO-87.93%

Recent News & Updates

May 12
Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

ONCCA BiotechsCA Market
7D4.2%-2.8%3.0%
1Y-33.3%11.1%0.7%

Return vs Industry: ONC underperformed the Canadian Biotechs industry which returned 11.1% over the past year.

Return vs Market: ONC underperformed the Canadian Market which returned 0.7% over the past year.

Price Volatility

Is ONC's price volatile compared to industry and market?
ONC volatility
ONC Average Weekly Movement8.7%
Biotechs Industry Average Movement13.0%
Market Average Movement10.6%
10% most volatile stocks in CA Market18.9%
10% least volatile stocks in CA Market4.3%

Stable Share Price: ONC is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ONC's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199826Matt Coffeyhttps://www.oncolyticsbiotech.com

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC.

Oncolytics Biotech Inc. Fundamentals Summary

How do Oncolytics Biotech's earnings and revenue compare to its market cap?
ONC fundamental statistics
Market CapCA$100.55m
Earnings (TTM)-CA$24.50m
Revenue (TTM)n/a

0.0x

P/S Ratio

-4.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ONC income statement (TTM)
RevenueCA$0
Cost of RevenueCA$949.77k
Gross Profit-CA$949.77k
Other ExpensesCA$23.55m
Earnings-CA$24.50m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.42
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ONC perform over the long term?

See historical performance and comparison